The Safety 77 Screening Panel is the modern industry benchmark for in vitro secondary pharmacology (off-target profiling). It was established as a consensus framework by the IQ Consortium DruSafe working group (Brennan et al., Nature Reviews Drug Discovery, 2024) and has replaced older, narrower paradigms like the standard Bowes-44 panel.
The panel consists of 77 high-risk targets (receptors, ion channels, enzymes, kinases, and transporters) that historical pharmaceutical metadata and clinical track records have strongly linked to severe adverse drug reactions (ADRs).
1. Composition and Target Class Distribution
The 77 targets are carefully distributed across major biological classes to maximize organ-system coverage (Cardiovascular, Central Nervous System, Gastrointestinal, Respiratory, etc.):
GPCRs (~30–44 targets): High-priority receptors where off-target activity causes acute clinical liabilities. Examples include 5HT2B(associated with cardiac valvulopathy), H1 (somnolence/sedation), alpha-1A (orthostatic hypotension), and M1-M3(anticholinergic side effects).
Ion Channels (~8 targets): Core cardiotoxicity and neurotoxicity gatekeepers. Beyond standard hERG, it screens Cav1.2, Nav1.5 (cardiac sodium), and Kv1.1.
Enzymes (~10–20 targets): Key metabolic and structural regulators like AChE (acetylcholinesterase), MAO-A/MAO-B, COX-1/COX-2, and PDEs (e.g., PDE3A, PDE4D).
Kinases (~8–10 targets): Screens for broad structural toxicity flags, including targets like FAK, KDR (VEGFR2), and Flt-1 (VEGFR1).
Transporters & Nuclear Receptors: Screens critical clearance/uptake machinery (e.g., NET, DAT, SERT) and endocrine liabilities (e.g., Glucocorticoid and Progesterone receptors).
2. Experimental Formats: Binding vs. Functional
Commercial Contract Research Organizations (such as Eurofins Discovery, Reaction Biology, and ICE Bioscience) typically deliver this panel in two formats, depending on your stage of lead optimization:
A. Radioligand / Competitive Binding Format
How it works: Highly automated, microplate-based displacement assays. A single high concentration of your lead molecule (typically 10 uM) is introduced to see if it displaces a known, radiolabeled or fluorescent control ligand from the target pocket.
The Output: Reported as a percentage inhibition (%inh). Hits are usually flagged if inhibition exceeds 50%.
Best For: Early Hit-to-Lead triage, rapid structural SAR exploration, and building computational safety-prediction algorithms.
B. Functional (Cell-Based / Enzymatic) Format
How it works: Evaluates the biological consequence of the binding event in living cells or active enzymatic matrices. For example, GPCRs are tracked via real-time cellular calcium flux or cAMP assays, while kinases are typically evaluated at near-physiological 1 mM ATP conditions to avoid false positives.
The Output: Generates a full 8-point or 10-point dose-response curve, yielding absolute IC50 or EC50 values.
Best For: Distinguishing agonists from antagonists (e.g., an agonist at 5HT2B is a severe cardiac risk, whereas an antagonist is clean), calculating explicit safety margins, and supporting IND-enabling regulatory packages (aligned with ICH S7A/B).
3. Standard Selection Criteria & Data Triage
When the multi-well screening data is returned, medicinal chemistry and toxicology teams triage the hits based on a Therapeutic Index (TI) approach rather than absolute potency alone:
[ Safety Margin ] = Target IC50 (from Safety Panel 77) / Anticipated Free Clinical Exposure (Cmax,u)
The Red Flag (TI < 10\ fold: If a compound inhibits an off-target like Nav1.5 or an opioid receptor at a concentration less than 10 times your free clinical Cmax, it represents an immediate developmental liability requiring structural modification.
The Acceptable Threshold: For the majority of the 77 non-cardiac targets, a 100-fold window between therapeutic efficacy and off-target activity is considered a clean safety profile for advancement.

